Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioPharma, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, has announced it has completed a private placement with net proceeds in excess of CAD5.4 million, after fees and expenses associated with the placement.
Subscribe to our email newsletter
The terms of the placement are for the purchase of common shares at $1.60 per share and include one warrant per share at an exercise price of $2.24 and have an expiry of five years from the date of issue.
"We expect that these funds will allow us to complete the Phase I component of the Polish trial and all the preparatory work required for the previously approved US Phase I clinical trial of L-DOS47 in combination with Pemetrexed and Carboplatin", stated Robert Verhagen, President & CEO of Helix.
ACM Alpha Management Consulting Est. provided financial advisory services to Helix in connection with this private placement.